SCLC has been treated as a single disease without patient stratification and exhibits genetic loss of both tumor suppressors RB1 and TP53, along with mutually exclusive expression of MYC paralog (MYC, MYCN, MYCL) [19,20,21,22,23]. This evidence concerns the gene MYC and small cell lung carcinoma.